摘要
近年来认为肿瘤免疫抑制最为重要的原因,是免疫细胞异常表达一些T细胞免疫抑制受体所介导的T细胞功能耗竭,与肿瘤的发生发展密切相关,而阻断这些免疫负调控受体通路可以使T细胞部分或全部恢复功能。本文就近年来新近发现的T细胞免疫抑制受体T细胞免疫球蛋白黏蛋白分子3(TIM-3)、淋巴细胞活化基因-3(LAG3)和B和T淋巴细胞弱化子(BTLA)在血液肿瘤介导T细胞免疫耐受中的作用及其靶向治疗研究进展作一综述,旨在为血液肿瘤的免疫靶向治疗提供新的思路。
The main mechanism of tumor immune suppression is due to the T cell exhaustion which is mediated by abnormal expression of T-cell immunosuppressive receptors in immune cells.Blocking these molecules may restore partial or all functions of T cells.This article reviews the advance on the role of the newly discovered T cell immunosuppressive receptors such as TIM-3,LAG-3 and BTLA,including their mediated T cell-immune tolerance and the study of targeted immunotherapy in hematological malignancies,so as to provide the new strategy for immune-targeted therapy for hematological malignancies.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2016年第5期1594-1597,共4页
Journal of Experimental Hematology
基金
国家自然科学基金(81100353
81270604
81400109)
中央高校基本科研业务费专项资金资助(21616108)
